IL102916A - Absorbent preparations based on training for the reduction of implant rejection mediated by pre-formed antibodies and a method for removing pre-formed antibodies - Google Patents

Absorbent preparations based on training for the reduction of implant rejection mediated by pre-formed antibodies and a method for removing pre-formed antibodies

Info

Publication number: IL102916A
Authority: IL; Israel
Prior art keywords: group; carbon atoms; hydrogen; alkyl; antigen
Prior art date: 1991-08-23

Application number

IL10291692A

Other languages

English (en)

Hebrew (he)

Other versions

IL102916A0 (en

Original Assignee

Alberta Res Council

Integris Baptist Med Center Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-23

Filing date

1992-08-23

Publication date

1999-03-12

1992-08-23 Application filed by Alberta Res Council, Integris Baptist Med Center Inc filed Critical Alberta Res Council

1992-08-23 Priority to IL12045392A priority Critical patent/IL120453A/en

1993-01-31 Publication of IL102916A0 publication Critical patent/IL102916A0/xx

1997-03-14 Priority to IL12045397A priority patent/IL120453A0/xx

1999-03-12 Publication of IL102916A publication Critical patent/IL102916A/en

Links

230000001404 mediated effect Effects 0.000 title claims abstract description 10
238000000034 method Methods 0.000 title claims description 37
239000000203 mixture Substances 0.000 title claims description 23
150000001720 carbohydrates Chemical class 0.000 claims abstract description 77
210000004369 blood Anatomy 0.000 claims abstract description 33
239000008280 blood Substances 0.000 claims abstract description 33
239000007787 solid Substances 0.000 claims abstract description 25
230000010412 perfusion Effects 0.000 claims abstract description 4
241000282414 Homo sapiens Species 0.000 claims description 91
239000000427 antigen Substances 0.000 claims description 55
102000036639 antigens Human genes 0.000 claims description 55
108091007433 antigens Proteins 0.000 claims description 55
125000004432 carbon atom Chemical group C* 0.000 claims description 38
229910052739 hydrogen Inorganic materials 0.000 claims description 31
239000001257 hydrogen Substances 0.000 claims description 31
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 27
238000002360 preparation method Methods 0.000 claims description 27
-1 monosaccharide glycoside Chemical class 0.000 claims description 25
125000000217 alkyl group Chemical group 0.000 claims description 22
229930182470 glycoside Natural products 0.000 claims description 20
125000002947 alkylene group Chemical group 0.000 claims description 18
229910052760 oxygen Inorganic materials 0.000 claims description 17
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
210000001124 body fluid Anatomy 0.000 claims description 16
239000010839 body fluid Substances 0.000 claims description 16
101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 claims description 15
150000002338 glycosides Chemical class 0.000 claims description 13
229910052717 sulfur Inorganic materials 0.000 claims description 13
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
239000011593 sulfur Substances 0.000 claims description 10
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
229920001542 oligosaccharide Polymers 0.000 claims description 9
239000001301 oxygen Substances 0.000 claims description 9
DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
229910052757 nitrogen Inorganic materials 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
125000005647 linker group Chemical group 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
125000001475 halogen functional group Chemical group 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
150000001412 amines Chemical group 0.000 claims description 3
238000002054 transplantation Methods 0.000 abstract description 21
230000002401 inhibitory effect Effects 0.000 abstract description 2
230000000250 revascularization Effects 0.000 abstract description 2
230000002238 attenuated effect Effects 0.000 abstract 1
210000002381 plasma Anatomy 0.000 description 76
235000014633 carbohydrates Nutrition 0.000 description 66
241000282898 Sus scrofa Species 0.000 description 42
230000001472 cytotoxic effect Effects 0.000 description 30
210000000056 organ Anatomy 0.000 description 25
210000004027 cell Anatomy 0.000 description 23
239000002953 phosphate buffered saline Substances 0.000 description 22
150000004043 trisaccharides Chemical class 0.000 description 20
230000027455 binding Effects 0.000 description 18
231100000433 cytotoxic Toxicity 0.000 description 17
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
210000003743 erythrocyte Anatomy 0.000 description 16
239000011159 matrix material Substances 0.000 description 14
230000002829 reductive effect Effects 0.000 description 14
OZIOWHWTZWIMCZ-MPUPURDASA-N B-Trisaccharide Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 OZIOWHWTZWIMCZ-MPUPURDASA-N 0.000 description 13
210000002966 serum Anatomy 0.000 description 13
210000001519 tissue Anatomy 0.000 description 13
210000003734 kidney Anatomy 0.000 description 12
230000009467 reduction Effects 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 10
238000003556 assay Methods 0.000 description 10
229910052804 chromium Inorganic materials 0.000 description 10
239000011651 chromium Substances 0.000 description 10
230000000295 complement effect Effects 0.000 description 10
230000009089 cytolysis Effects 0.000 description 10
210000003292 kidney cell Anatomy 0.000 description 10
239000000243 solution Substances 0.000 description 10
150000002016 disaccharides Chemical class 0.000 description 9
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 8
150000002772 monosaccharides Chemical class 0.000 description 7
150000002482 oligosaccharides Chemical class 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
241000283690 Bos taurus Species 0.000 description 6
238000002965 ELISA Methods 0.000 description 6
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 6
241001494479 Pecora Species 0.000 description 6
229920001213 Polysorbate 20 Polymers 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
125000000524 functional group Chemical group 0.000 description 6
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
241000894007 species Species 0.000 description 6
241000282412 Homo Species 0.000 description 5
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000002949 hemolytic effect Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
238000001179 sorption measurement Methods 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
239000000386 donor Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
238000002689 xenotransplantation Methods 0.000 description 4
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
206010018910 Haemolysis Diseases 0.000 description 3
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
229940125782 compound 2 Drugs 0.000 description 3
230000001461 cytolytic effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
230000008588 hemolysis Effects 0.000 description 3
150000002431 hydrogen Chemical class 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
210000002925 A-like Anatomy 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229930186217 Glycolipid Natural products 0.000 description 2
241001272567 Hominoidea Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
241000288935 Platyrrhini Species 0.000 description 2
241000288906 Primates Species 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
241000282887 Suidae Species 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
210000001557 animal structure Anatomy 0.000 description 2
229960002319 barbital Drugs 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229930182830 galactose Natural products 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
150000004678 hydrides Chemical class 0.000 description 2
125000001165 hydrophobic group Chemical group 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
238000005497 microtitration Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
150000004760 silicates Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
125000005999 2-bromoethyl group Chemical group 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000182988 Assa Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
229930182475 S-glycoside Natural products 0.000 description 1
208000003441 Transfusion reaction Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000004308 accommodation Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
FJGXDMQHNYEUHI-LRFIHEIOSA-N alpha-D-GalNpAc-(1->3)-beta-D-GalpNAc Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1O[C@@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 FJGXDMQHNYEUHI-LRFIHEIOSA-N 0.000 description 1
YMHAMDVCLHZMOT-QZHFAHFZSA-N alpha-D-GalpNAc-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](NC(C)=O)[C@H](O[C@H]2[C@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@@H]1O YMHAMDVCLHZMOT-QZHFAHFZSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
VJLOFJZWUDZJBX-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;chloride Chemical compound [Cl-].OCC[NH2+]CCO VJLOFJZWUDZJBX-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000009582 blood typing Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
150000008271 glucosaminides Chemical class 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002339 glycosphingolipids Chemical class 0.000 description 1
239000000348 glycosyl donor Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
244000144980 herd Species 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
238000002955 isolation Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229910052622 kaolinite Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
125000004492 methyl ester group Chemical group 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000005373 porous glass Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012910 preclinical development Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
150000004044 tetrasaccharides Chemical class 0.000 description 1
150000003569 thioglycosides Chemical class 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000003643 water by type Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Anesthesiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Cardiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Virology (AREA)
Zoology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
External Artificial Organs (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL10291692A 1991-08-23 1992-08-23 Absorbent preparations based on training for the reduction of implant rejection mediated by pre-formed antibodies and a method for removing pre-formed antibodies IL102916A (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
IL12045392A IL120453A (en)	1991-08-23	1992-08-23	Anti-rejection drug-mediated drug of foreign implant rejection
IL12045397A IL120453A0 (en)	1991-08-23	1997-03-14	Composition for attenuating antibody-mediated xenograft rejection

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US74952991A	1991-08-23	1991-08-23

Publications (2)

Publication Number	Publication Date
IL102916A0 IL102916A0 (en)	1993-01-31
IL102916A true IL102916A (en)	1999-03-12

Family

ID=25014128

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10291692A IL102916A (en)	1991-08-23	1992-08-23	Absorbent preparations based on training for the reduction of implant rejection mediated by pre-formed antibodies and a method for removing pre-formed antibodies

Country Status (8)

Country	Link
US (4)	US5651968A (de)
EP (1)	EP0661980B1 (de)
JP (1)	JP3201523B2 (de)
AT (1)	ATE232730T1 (de)
AU (1)	AU666128B2 (de)
DE (1)	DE69232928D1 (de)
IL (1)	IL102916A (de)
WO (1)	WO1993003735A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995031209A1 (en) *	1994-05-13	1995-11-23	Baxter International Inc.	Prevention of hyperacute rejection in pig to primate organ transplant
US5785966A (en) *	1994-06-15	1998-07-28	Coles; John G.	Inhibition of human xenogenic or allogenic antibodies to reduce xenograft or allograft rejection in human recipients
US20040047865A1 (en) *	1995-08-31	2004-03-11	Warner Richard Gareth	Compositions and their uses
EP0775493A3 (de) *	1995-11-22	1998-08-12	Baxter International Inc.	Extrakorporeale xenogene Organperfusion nach Antikörper-Verringerung durch Immunoapherese
WO2001058510A1 (en) *	2000-02-08	2001-08-16	Glycorex Transplantation Ab	Oligosaccharide supports for e.g. removal of antibodies from blood
AU1404597A (en) *	1995-12-21	1997-07-17	Procur Ab	Galactopyranosides and their use
US7014049B2 (en)	1996-12-23	2006-03-21	Glycorex Transplantation Ab	Device for bio-affinity material
US6214540B1 (en)	1997-03-26	2001-04-10	University Of Maryland Biotechnology Institute	Chemokines that inhibit immunodeficiency virus infection and methods based thereon
PT970114E (pt) *	1997-04-18	2006-12-29	Novartis Ag	Neoglicoproteínas
US6096725A (en) *	1997-07-02	2000-08-01	Neose Technologies, Inc.	Methods of using αGal oligosaccharides as immune system targeting agents
US6548631B1 (en)	1997-09-16	2003-04-15	BIOMéRIEUX, INC.	Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6756361B1 (en) *	1997-10-14	2004-06-29	Nabi	Enterococcus antigens and vaccines
AU761831B2 (en) *	1998-04-15	2003-06-12	Bioscience 2002 Llc	Inhibition of xenoreactive antibodies
WO1999055396A1 (en)	1998-04-27	1999-11-04	Surmodics, Inc.	Bioactive agent release coating
US8197430B1 (en)	1998-05-22	2012-06-12	Biopheresis Technologies, Inc.	Method and system to remove cytokine inhibitor in patients
US6620382B1 (en)	1998-05-22	2003-09-16	Biopheresis Technologies, Llc.	Method and compositions for treatment of cancers
US6358930B1 (en)	1998-05-28	2002-03-19	Synsorb Biotech Inc.	Treatment of C. difficile toxin B associated conditions
US6013635A (en) *	1998-05-28	2000-01-11	Synsorb Biotech, Inc.	Treatment of C. difficile toxin B associated conditions
US6399578B1 (en) *	1998-12-09	2002-06-04	La Jolla Pharmaceutical Company	Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
JP2002531531A (ja) *	1998-12-09	2002-09-24	ラホヤファーマシューティカルカンパニー	循環している抗体を減少させるための方法および処方物
AU2408700A (en) *	1999-01-11	2000-08-01	Baxter International Inc.	Method and apparatus for selectively removing xenoreactive antibodies from blood, serum or plasma
DE60044717D1 (de) *	1999-05-10	2010-09-02	Paolo Brenner	Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US6379708B1 (en) *	1999-11-20	2002-04-30	Cytologic, Llc	Method for enhancing immune responses in mammals
EP1257558A1 (de) *	2000-01-13	2002-11-20	Alchemia Pty Ltd	Verfahren zur synthese von alpha-d-gal (1- 3) gal-haltigen oligosacchariden
DE10036742A1 (de) *	2000-07-27	2002-02-21	Aesku Lab Diagnostika	Vorrichtung zur Behandlung von Immunerkrankungen
FI20011403A7 (fi) *	2001-06-29	2002-12-30	Carbion Oy	Menetelmä ja koostumukset vatsan sairauksien hoitoon
US7097850B2 (en) *	2002-06-18	2006-08-29	Surmodics, Inc.	Bioactive agent release coating and controlled humidity method
JP2007532187A (ja)	2004-04-06	2007-11-15	サーモディクス，インコーポレイティド	生物活性物質のためのコーティング組成物
JP2008511340A (ja) *	2004-04-30	2008-04-17	バイオフェレシステクノロジーズ，インコーポレイテッド	患者において可溶性ｔｎｆｒ１、可溶性ｔｎｆｒ２、および可溶性ｉｌ２を除去する方法およびシステム
US20060099169A1 (en) *	2004-10-13	2006-05-11	Ilypsa, Inc.	Toxin binding compositions
US20060078534A1 (en) *	2004-10-13	2006-04-13	Dominique Charmot	Toxin binding compositions
FR2886298A1 (fr) *	2005-05-24	2006-12-01	Ifremer	Anticorps ou fragment d'anticorps couple a un agent immunogene
US20070065514A1 (en) *	2005-09-22	2007-03-22	Howell Mark D	Method for enhancing immune responses in mammals
US20080075690A1 (en) *	2006-09-22	2008-03-27	Mark Douglas Howell	Method for enhancing immune responses in mammals
US9045516B2 (en) *	2007-04-16	2015-06-02	Suri Saranathan Iyer	Synthetic ligands for the differentiation of closely related toxins and pathogens
US9420770B2 (en)	2009-12-01	2016-08-23	Indiana University Research & Technology Corporation	Methods of modulating thrombocytopenia and modified transgenic pigs
EP2698636A1 (de)	2012-08-13	2014-02-19	Fundació Institut d'Investigació Biomèdica de Bellvitge	Verfahren und Reagenzien zur Vorbeugung und/oder Behandlung von Transplantatabstoßung
EP3013365B1 (de) *	2013-06-26	2019-06-05	Academia Sinica	Rm2-antigene und verwendung davon
US9994605B2 (en)	2014-03-13	2018-06-12	Universitaet Basel	Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein
CA2996073A1 (en)	2015-09-16	2017-03-23	Universitat Basel	Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
CN110699328B (zh) *	2019-08-21	2022-07-19	山东省滨州畜牧兽医研究院	一种b型猪肠道病毒及其应用
CN114920788B (zh) *	2022-05-30	2024-07-30	天津科技大学	人乳三糖半乳糖基乳糖的制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1544908A (en) *	1975-07-08	1979-04-25	Chembiomed Ltd	Artificial oligosaccharide antigenic determinants
US4362720A (en) *	1977-04-14	1982-12-07	Chembiomed Ltd.	Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
US5079353A (en) *	1987-12-02	1992-01-07	Chembiomed, Ltd.	Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5240601A (en) *	1988-11-09	1993-08-31	Chembiomed, Ltd.	Affinity supports for hemoperfusion
US5149425A (en) *	1988-11-09	1992-09-22	Chembiomed, Ltd.	Affinity supports for hemoperfusion

1992
- 1992-08-21 WO PCT/US1992/007071 patent/WO1993003735A1/en not_active Ceased
- 1992-08-21 DE DE69232928T patent/DE69232928D1/de not_active Expired - Lifetime
- 1992-08-21 AU AU25059/92A patent/AU666128B2/en not_active Ceased
- 1992-08-21 JP JP50461193A patent/JP3201523B2/ja not_active Expired - Fee Related
- 1992-08-21 AT AT92918977T patent/ATE232730T1/de not_active IP Right Cessation
- 1992-08-21 US US07/933,466 patent/US5651968A/en not_active Expired - Lifetime
- 1992-08-21 EP EP92918977A patent/EP0661980B1/de not_active Expired - Lifetime
- 1992-08-23 IL IL10291692A patent/IL102916A/en not_active IP Right Cessation
1995
- 1995-06-02 US US08/458,683 patent/US6607723B1/en not_active Expired - Fee Related
- 1995-06-02 US US08/460,094 patent/US5767093A/en not_active Expired - Fee Related
- 1995-06-02 US US08/459,405 patent/US5695759A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0661980A4 (de)	1994-11-24
WO1993003735A1 (en)	1993-03-04
ATE232730T1 (de)	2003-03-15
US5767093A (en)	1998-06-16
JPH07501237A (ja)	1995-02-09
AU666128B2 (en)	1996-02-01
IL102916A0 (en)	1993-01-31
EP0661980B1 (de)	2003-02-19
DE69232928D1 (de)	2003-03-27
EP0661980A1 (de)	1995-07-12
JP3201523B2 (ja)	2001-08-20
AU2505992A (en)	1993-03-16
US6607723B1 (en)	2003-08-19
US5651968A (en)	1997-07-29
US5695759A (en)	1997-12-09

Legal Events

Date	Code	Title
1999-09-22	FF	Patent granted
2000-02-17	KB	Patent renewed
2002-11-10	KB	Patent renewed
2006-10-30	KB	Patent renewed
2011-04-28	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0661980B1 (de)	2003-02-19	Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten
Wright et al.	1986	Adhesion-promoting receptors on human macrophages recognize Escherichia coli by binding to lipopolysaccharide.
Garratty	2004	Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs
Pilatte et al.	1993	Sialic acids as important molecules in the regulation of the immune system: pathophysiological implications of sialidases in immunity
Cooper et al.	1993	Identification of α-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man
NEETHLING et al.	1994	PROTECTION OF PIG KIDNEY (PK15) CELLS FROM THE CYTOTOXIC EFFECT OF ANTI-PIG ANTIBODIES BY α-GALACTOSYL OLIGOSACCHARIDES1
Holgersson et al.	2005	Characteristics of protein–carbohydrate interactions as a basis for developing novel carbohydrate‐based antirejection therapies
Nyame et al.	1996	Schistosoma mansoniInfection in Humans and Primates Induces Cytolytic Antibodies to Surface LexDeterminants on Myeloid Cells
Garratty	2008	Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion
Allison et al.	1973	Effects of endotoxin on macrophages and other lymphoreticular cells
US5977079A (en)	1999-11-02	Compositions for attenuating antibody- mediated xenograft rejection in human recipients
Handman et al.	1987	Carbohydrate antigens as possible parasite vaccines: A case for the Leishmania glycolipid
Spitalnik et al.	1985	Anti-My-28, an antigranulocyte mouse monoclonal antibody, binds to a sugar sequence in lacto-N-neotetraose
Zhu	2000	BINDING OF HUMAN NATURAL ANTIBODIES TO NONαGal XENOANTIGENS ON PORCINE ERYTHROCYTES1
JPH07504222A (ja)	1995-05-11	化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制
Brondz et al.	1975	Enrichment of effector T lymphocytes specific to H‐2 antigens by elution from allogeneic target cells and characterization of the eluted lymphocyte population
JP2001518074A (ja)	2001-10-09	Ｂ細胞の免疫寛容誘導
CA2116138C (en)	2006-04-04	Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
Rydberg et al.	1999	α-Gal epitopes in animal tissue glycoproteins and glycolipids
IL120453A (en)	1998-12-06	Anti-rejection drug-mediated drug of foreign implant rejection
Kyoizumi et al.	1985	A lectinlike receptor on murine macrophage cell line cells, Mm1: involvement of sialic acid-binding sites in opsonin-independent phagocytosis for xenogeneic red cells
EP0847280B1 (de)	2002-11-20	Zusammensetzungen und ihre anwendungen gegen die hyperakute abstossung von transplantaten und bestimmte krankheiten
US20250177448A1 (en)	2025-06-05	New use of peg-phospholipid molecules
US20040047865A1 (en)	2004-03-11	Compositions and their uses
Hakomori	1986	Tumor-associated glycolipid markers: possible targets for drug and Immuno-toxin delivery